Eplontersen vs Nexiguran ziclumeran

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Transthyretin Amyloidosis with Cardiomyopathy

Shared mechanism: Transthyretin (TTR) · full Transthyretin Amyloidosis with Cardiomyopathy pipeline

Eplontersen · Wainua

Marketed by AstraZeneca and partners

Phase 3 in Transthyretin Amyloidosis with Cardiomyopathyantisense
Partial signal

NCT04136171 · Phase 3 · completed

This was a large randomized, double-blind, placebo-controlled trial of 1,432 treated patients with a hard clinical primary endpoint, cardiovascular death and recurrent cardiovascular events. Eplontersen did not reduce this endpoint significantly compared with placebo, so the trial is well-designed evidence of no clear benefit rather than strong evidence of a positive effect.

Next expected readout: August 2029 · NCT05667493 (registry estimate)

Reported efficacy

Composite Outcome of Cardiovascular (CV) Mortality and Recurrent CV Clinical Events up to Week 140 (Baseline up to Week 140): CARDIO-TTRansform primary composite: rate ratio 0.89 (95% CI 0.73 to 1.09), P=0.28; no significant reduction. (missed)

Result source: NCT04136171

Nexiguran ziclumeran

Developed by Regeneron Pharmaceuticals

Phase 3 in Transthyretin Amyloidosis with Cardiomyopathygene editing (CRISPR)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2027 · NCT06128629 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Transthyretin Amyloidosis with Cardiomyopathy

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Nexiguran ziclumeran: no structured comparison results are available for Transthyretin Amyloidosis with Cardiomyopathy.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Eplontersen
CARDIO-TTRansform primary composite: rate ratio 0.89 (95% CI 0.73 to 1.09), P=0.28; no significant reduction. NCT04136171 · Phase 3 · design grade: moderate · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Eplontersen's landscape · Nexiguran ziclumeran's landscape